NAMPT and metabolic dysfunction-associated steatotic liver disease: Recent clinical studies have revealed abnormal levels of leptin, visfatin and chemerin in the blood and liver of patients with NAFLD, chronic hepatitis and hepatocellular carcinoma [31–42].